10:25 AM EDT, 10/22/2025 (MT Newswires) -- Boston Scientific ( BSX ) raised its full-year guidance on Wednesday as the medical device supplier's third-quarter results came in stronger than Wall Street's estimates, driven by a 22% revenue surge in its cardiovascular segment.

The company now expects adjusted earnings between $3.02 and $3.04 per share for 2025, up from up from its prior estimate of $2.95 to $2.99. Sales are pegged to grow about 20% on a reported basis, compared with the previous forecast of 18% to 19%. Analysts surveyed by FactSet expect non-GAAP EPS of $2.98 on sales of $19.88 billion, up from last year's $2.51 and $16.75 billion, respectively.

For the September quarter, adjusted EPS rose to $0.75 from $0.63 a year earlier and surpassed the $0.71 consensus. Overall sales grew 20% on a reported basis to $5.07 billion and exceeded analysts' $4.97 billion view.

Third-quarter sales in the cardiovascular business surged 22% year over year to $3.34 billion, driven by a 24% advance in cardiology. The MedSurg division jumped 16% to $1.72 billion amid double-digit gains in endoscopy and urology. The company logged revenue growth across all the regions it operates in, including a 27% rise in the US.

Shares of Boston Scientific ( BSX ) were up 4.1% in Wednesday trade. The stock has risen about 16% so far this year.

For the current quarter, the biotech firm expects adjusted EPS of $0.77 to $0.79 on sales growth of 14.5% to 16.5%. Analysts are looking for non-GAAP EPS of $0.76 on sales of $5.18 billion.

The revenue outlook for the December quarter excludes an approximately 200-basis-point tailwind from foreign exchange, Chief Financial Officer Jonathan Monson said during an earnings call, according to a FactSet transcript.

Price: 103.90, Change: +4.00, Percent Change: +4.00